New hope for liver cancer patients with limited options after immunotherapy fails
NCT ID NCT07514455
First seen Apr 11, 2026 · Last updated May 15, 2026 · Updated 6 times
Summary
This study tests the drug regorafenib in about 20 adults with advanced liver cancer and moderate liver impairment (Child-Pugh B) whose cancer worsened after first-line immunotherapy. Participants take regorafenib pills daily for 3 weeks, then 1 week off, until the cancer progresses or side effects become too severe. The goal is to see if this treatment can delay cancer growth longer than the expected 1-2 months without treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DISEASE PROGRESSION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Asan Medical Center
Seoul, 05505, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.